Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-15
    E.g., 2018-07-15

Articles

8922 items
11:18 AM, Jun 13, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Hypercholesterolemia Patient sample and mouse studies suggest inhibiting LIMA1 could help treat hypercholesterolemia. Whole-genome sequencing of patient plasma samples identified an association between a rare frameshift variant of LIMA1 and low levels of LDL-C...
11:17 AM, Jun 13, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and fruit fly studies suggest promoting NAD+ synthesis could help treat PD caused by GBA mutations. In neurons generated via induced pluripotent stem (iPS) cells from a patient harboring a...
11:17 AM, Jun 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Liver cancer, colorectal cancer Cell culture and mouse studies suggest inhibiting CPT1A alone or in combination with VEGF inhibition could help treat hepatocellular carcinoma and colorectal cancer. In a mouse colorectal cancer cell line cultured...
11:17 AM, Jun 13, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest a PEG-based hydrogel loaded with lysostaphin could help treat orthopedic implant Staphylococcus infections. The antimicrobial enzyme lysostaphin is encapsulated in a hydrogel consisting of four-arm PEG macromers that...
12:06 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib decreased...
12:06 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer; non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting PHIP could help treat triple-negative breast cancer (TNBC) and NSCLC. In two human TNBC cell lines, shRNA targeting PHIP decreased colony...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and rat studies suggest pericardial fluid-treated cardiospheres could help treat MI. In primary rat cardiospheres, levels of cardiac stem cell markers and growth factors were higher when cultured in pericardial...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest activating NFE2L2 could help treat ALS by promoting normal folding of mutant SOD1. Crystallographic analyses of an ALS-associated SOD1 mutant complexed with a library of cysteine-reactive...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome Mouse studies identified a macrocyclic Trypanosoma rhodesain inhibitor that could help treat African trypanosomiasis. Screening of a library of cysteine protease inhibitors, in vitro activity and parasite culture assays, and structure-based optimization of...
3:47 PM, Jun 05, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Hypertriglyceridemia Rat studies suggest combined inhibition of MMP1 and MMP3 could help treat hypertriglyceridemia. In a rat model of diet-induced hypertriglyceridemia, subcutaneous administration of a previously reported dual MMP1/MMP3 inhibitor decreased liver weight, serum triacylglyceride,...

Pages